Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AMGN crawled date : 2020 - 12 - 23 save search
Cytokinetics Regains European Rights to Omecamtiv MecarbilCompany is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for Co-Commercialization and Licensing
Published: 2020-12-23 (Crawled : 18:00) - biospace.com/
CYTK | $66.35 -1.78% -1.81% 1.2M
|
Health Technology
|
| O: -0.39%
H: 3.9%
C: 3.45%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: 0.22%
H: 0.95%
C: 0.66%
license commercialization
Amgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Medicines Development for Global Health
Published: 2020-12-22 (Crawled : 00:00) - biospace.com/
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -0.7%
H: 0.33%
C: -2.1%
license treatment
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.